Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study
Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study
复制标题
DOI：
10.1007/s10549-020-05668-5
复制
发表时间：
2020-05-12
影响因子：
3.8
通讯作者：
Sakai, Yoshitada
中科院分区：
文献类型：
--
作者：
Saito, Takashi;Ono, Rei;Sakai, Yoshitada
目的研究接受芳香化酶抑制剂（AI）辅助治疗的乳腺癌患者的身体活动（PA）与骨健康的关系。方法在这项单中心观察性研究中，我们纳入了接受辅助AI治疗的原发性激素受体阳性乳腺癌绝经后妇女。我们评估患者的骨健康[骨矿物质密度（BMD）和骨转换的生物标志物]作为主要结果。使用Baecke体力活动问卷（BPAQ）和加速度计评估PA。在调整年龄、体重指数、吸烟史和AI治疗持续时间后进行多元回归分析。对于缺失数据，采用多重插补分析。结果53例入组患者的平均年龄为67.4 ± 8.4岁。AI给药的平均持续时间为25.7 ± 18.9个月。最常使用的AI是阿那曲唑（73.6%）。虽然与BMD无关，但PA与骨转换相关。血清I型胶原氨基末端前肽，一种骨形成标志物，仅与轻度PA相关（t =-2.55，p = 0.015），而抗酒石酸酸性磷酸酶5 b（一种骨吸收标志物）与BPAQ子量表和轻度PA中的工作指数相关。（t =-2.28，p = 0.028，t =-2.26，p = 0.031）。所有患者的结果与多重插补分析中观察到的结果相似。结论在接受AI治疗的癌症患者中，PA与骨转换显著相关。在各种PA强度和PA域中，光PA和工作域PA是最重要的因素。
Purpose To examine the association of physical activity (PA) with bone health among patients with breast cancer receiving adjuvant aromatase inhibitor (AI) treatment. Methods In this single-center observational study, we enrolled postmenopausal women with primary hormone receptor-positive breast cancer who were receiving adjuvant AI treatment. We assessed patient bone health [bone mineral density (BMD) and biomarkers of bone turnover] as main outcomes. PA was assessed using Baecke physical activity questionnaires (BPAQ) and an accelerometer. Multiple regression analysis was performed after adjustment for age, body mass index, smoking history and duration of AI treatment. For missing data, multiple imputation analysis was adapted. Results The mean age of the 53 enrolled patients was 67.4 +/- 8.4 years. The mean duration of AI administration was 25.7 +/- 18.9 months. The most frequently administered AI was anastrozole (73.6%). Although not related to BMD, PA was related to bone turnover. Serum collagen type I amino-terminal propeptide, a bone formation marker, was associated with only light PA (t = - 2.55, p = 0.015), while tartrate-resistant acid phosphatase 5b, a bone absorption marker, was associated with work index in the BPAQ subscale and light PA (t = - 2.28, p = 0.028, t = - 2.26, p = 0.031, respectively). The results for all patients were similar to those observed in the multiple imputation analysis. Conclusion PA was significantly associated with bone turnover among cancer patients receiving AI treatment. Light PA and PA in the work domain were the most important factors among various PA intensities and PA domains.